Half-life
~1–2 minutes plasma; slow-release formulations extend duration
Evidence Level
Moderate Evidence
Mechanism of Action
Binds VPAC1/VPAC2 receptors. Potent vasodilator, bronchodilator, and immunomodulator. Anti-inflammatory via IL-10 upregulation and Th2 shift. Circadian pacemaker neurotransmitter in SCN.
Published Research Ranges & Study Context
Studies have administered: 200ng/kg/min IV infusion; inhaled formulations in PAH studies
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Phase 2 trial in pulmonary arterial hypertension showed hemodynamic improvements. Immune dysregulation studies (including CIRS/MCAS research by Shoemaker) published.
Moderate Evidence
Phase 1/2 human trials available
Side Effects Observed in Research
Hypotension (vasodilatory mechanism), flushing, tachycardia at pharmacological doses in trials
Available Configurations (SKU Reference)
VIP5
VIP10
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on VIP — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.